Cargando…
KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
Autores principales: | Lopez-Crapez, E, Mineur, L, Emptas, H, Lamy, P-J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844033/ https://www.ncbi.nlm.nih.gov/pubmed/20160721 http://dx.doi.org/10.1038/sj.bjc.6605582 |
Ejemplares similares
-
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Cremolini, C, et al.
Publicado: (2010) -
Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008) -
Coronavirus Antibodies in Bat Biologists
por: Stockman, Lauren J., et al.
Publicado: (2008) -
KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition
por: Rouleau, E, et al.
Publicado: (2008) -
Necessity of globally implementing the comprehensive mental health action plan: World Health Organization
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2015)